|
1
|
Rassy E, Bakouny Z, Choueiri TK, Van Allen
AM, Fizazi K, Greco FA and Pavlidis N: The role of site-specific
therapy for cancers of unknown primary: A meta-analysis. Eur J
Cancer. 127:118–122. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Laprovitera N, Riefolo M, Ambrosini E,
Klec C, Pichler M and Ferracin M: Cancer of unknown primary:
Challenges and progress in clinical management. Cancers (Basel).
13(451)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Parisi S, Gambardella C, Ruggiero R,
Tolone S, Iovino F, Lucido FS, Fisone F, Lanza Volpe M, Cozzolino
G, Mongardini FM, et al: Rare axillary cancer of unknown primary
originating from the breast of a 64-year-old male patient: A case
report and literature review. Oncol Lett. 27(86)2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Krämer A, Bochtler T, Pauli C, Baciarello
G, Delorme S, Hemminki K, Mileshkin L, Moch H, Oien K, Olivier T,
et al: Cancer of unknown primary: ESMO Clinical Practice Guideline
for diagnosis, treatment and follow-up. Ann Oncol. 34:228–246.
2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rassy E, Assi T and Pavlidis N: Exploring
the biological hallmarks of cancer of unknown primary: Where do we
stand today? Br J Cancer. 122:1124–1132. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kato S, Alsafar A, Walavalkar V,
Hainsworth J and Kurzrock R: Cancer of unknown primary in the
molecular era: Trends. Cancer. 7:465–477. 2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kim KW, Krajewski KM, Jagannathan JP,
Nishino M, Shinagare AB, Hornick JL and Ramaiya NH: Cancer of
unknown primary sites: What radiologists need to know and what
oncologists want to know. AJR Am J Roentgenol. 200:484–492.
2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Qaseem A, Usman N, Jayaraj JS, Janapala RN
and Kashif T: Cancer of unknown primary: A review on clinical
guidelines in the development and targeted management of patients
with the unknown primary site. Cureus. 11(e5552)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Takamizawa S, Shimoi T, Yoshida M, Tokura
M, Yazaki S, Mizoguchi C, Saito A, Kita S, Yamamoto K, Kojima Y, et
al: Diagnostic value of tumor markers in identifying favorable or
unfavourable subsets in patients with cancer of unknown primary: A
retrospective study. BMC Cancer. 22(412)2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Es HA, Mahdizadeh H, Asl AAH and Totonchi
M: Genomic alterations and possible druggable mutations in
carcinoma of unknown primary (CUP). Sci Rep.
11(15112)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Holdenrieder S, Pagliaro L, Morgenstern D
and Dayyani F: Clinically meaningful use of bloodtumor markers in
oncology: Biomed Res. Int. 2016(9795269)2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lee T, Teng TZJT and Shelat VG:
Carbohydrate antigen 19-9 - tumor marker: Past, present and future.
World J Gastrointest Surg. 12:468–490. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Al-Khallaf H, Monoghan P, Ourfali A,
Elsammak M, Ambrosio C, Sodi R and Poovathumkadavil A: The highest
ever reported level of carbohydrate antigen 19-9: A case report. J
Med Cases. 2:71–75. 2011.
|
|
14
|
Inoue N, Matsumoto G, Sumitomo S, Sirakawa
A, Mandai K, Kawamura T and Uno K: Cancer of unknown primary with
presumptive pancreatic cancer treated with FOLFIRINOX. J Med Cases.
12:442–445. 2021.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Kasi PM, Kamatham S, Shahjehan F, Li Z,
Johnson PW, Merchea A and Colibaseanu DT: BRAF-V600E and
microsatellite instability prediction through CA-19-9/CEA ratio in
patients with colorectal cancer. J Gastrointest Oncol. 11:236–241.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kelley RK, Bridgewater J, Gores GJ and Zhu
AX: Systemic therapies for intrahepatic cholangiocarcinoma. J
Hepatol. 72:353–363. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kopetz S, Grothey A, Yaeger R, Van Cutsem
E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS,
et al: Encorafenib, binimetinib, and cetuximab in BRAF
V600E-Mutated colorectal cancer. N Engl J Med. 381:1632–1643.
2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tabernero J, Ros J and Élez E: The
evolving treatment landscape in BRAF-V600E-mutated metastatic
colorectal cancer. Am Soc Clin Oncol Educ Book. 42:1–10.
2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bernocchi O, Sirico M, Corona SP, Strina
C, Milani M, Cappelletti MR, Ferrero G, Ziglioli N, Cervoni V,
Macchiavelli A, et al: Tumor type agnostic therapy carrying BRAF
Mutation: Case reports and review of literature. Pharmaceuticals
(Basel). 14(159)2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Arozarena I and Wellbrock C: Overcoming
resistance to BRAF inhibitors. Ann Transl Med.
5(387)2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Vazzano J and Chen W: Liver and
intrahepatic bile ducts: Intrahepatic cholangiocarcinoma (small and
large duct types). Hagen CE (ed). PathologyOutlines.com, Inc., Bingham Farms, MI,
2024.
|
|
22
|
Subbiah V, Lassen U, Élez E, Italiano A,
Curigliano G, Javle M, de Braud F, Prager GW, Greil R, Stein A, et
al: Dabrafenib plus trametinib in patients with
BRAFV600E-mutated biliary tract cancer (ROAR): A phase
2, open-label, single-arm, multicentre basket trial. Lancet Oncol.
21:1234–1243. 2020.PubMed/NCBI View Article : Google Scholar
|
